PDE9 inhibitors for treatment of sickle cell disease

摘要

The present disclosure relates to a PDE9 inhibitor and a pharmaceutical composition comprising a PDE9 inhibitor. In one embodiment, the oral pharmaceutical composition comprises about 100 mg to about 300 mg of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3 -Tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazine-8-one (Compound 1), or a pharmaceutically acceptable salt, solvate or polymorph thereof; A filler selected from about 4% to about 6% by weight of pregelatinized starch and/or from about 15% to about 50% microcrystalline cellulose; And a processing aid selected from about 1% to about 2.5% by weight of colloidal silicon dioxide and/or about 0.5% to about 1.5% by weight of magnesium stearate, wherein the pharmaceutical composition comprises a solid suitable for administration to a patient. It exists in the form of tablets. In some embodiments, the composition has a friability of less than about 0.3% weight loss and a disintegration time of less than about 15 minutes as measured by USP friability and USP disintegration test.